Ravoxertinib

(Synonyms: GDC-0994)
52 Cited Publications
Avis client

Based on 52 publication(s) in Google Scholar

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.74%
  • CAS No.: 1453848-26-4
  • Formule: C21H18ClFN6O2
  • Masse moléculaire:440.86
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Ravoxertinib

More
Customer Validation & Images
RT-PCRCell Proliferation/Viability AssayIP
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • IP
  • RT-PCR
  • RT-PCR

Voir tous les produits spécifiques à Isoform ERK

More
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00